Thomas Niel

Thomas Niel

Expertise: Micro-Cap Stocks, Shareholder Activist Stocks, Value Stocks

Education: Bachelors in Accounting, CFA Program Participant (Completed Level I in 2017)

About Thomas:
Thomas Niel is an investment writer at InvestorPlace. With a professional background in accounting and financial analysis, his understanding of both words and figures pays dividends when writing clear, concise stock analysis.

A value investor at heart, Thomas looks at the fundamentals. Peer analysis and earnings multiples rarely tell the whole story. But, Thomas believes valuation metrics are a great starting point to separate the wheat from the chaff.

His work has appeared at several websites, including Seeking Alpha and TipRanks. Outside of investment research, Thomas provides inbound marketing content to the investment management industry.

You can follow Thomas on Twitter and check out his track record on TipRanks.

Recent Articles

Shares Could Go Higher, but Nvidia Stock Is Overvalued and Very Risky

But the other chip names are gunning for the same markets. All bets are off whether Nvidia will win in the 2020s. But at the current valuation, investors who want to enter NVDA stock today must make a pricey bet.

This Turnaround May Already Be Priced into GE Stock

General Electric's turnaround is still in progress. But the recent rally in the GE stock price may already factor in success. All bets are off whether GE or soar or sink in its turnaround. I'm not willing to take that risk. But investors who believe that GE will not only survive, but thrive as a leaner entity, should consider buying shares today.

All Bets Are Off With Square Stock as Rivals Heat Up Payments Competition

At Square stock's current valuation, investors should stay on the sidelines. All bets are off where SQ stock will trade in 2020.

Microsoft Stock Is Fairly Valued, but Azure’s Success Will Drive It Higher

There are a few risks. If Azure growth starts to slow, investors may not continue to give Microsoft stock such a high valuation. It may not fall to the valuation levels of Oracle (NYSE:ORCL) and IBM (NYSE:IBM), but its valuation on par with Alphabet may vanish. The competition could also get tougher with AWS; expect the two "cloud kings" to fight toe-to-toe for the biggest piece of the enterprise cloud pie.Compared to other opportunities, Microsoft stock is a solid play. Consider the risks and valuation, but there may be more upside in the near-term.

Don’t Bet on Tilray Stock Surviving the Cannabisphere Meltdown

Tilray stock is a minefield of risk. "Cannabis 2.0" could improve their fortunes. But a myriad of risks remain. With $450 million in convertible notes coming due in 2023, TLRY needs to improve its cash situation. Unless the company is swimming in green (cash, not pot) by then, Tilray will need a capital infusion to stay afloat. Add in potential selling pressure from Privateer shareholders unloading their position, and there's too many fleas on this dog for my taste.

Rebounding Teva Stock Could Climb Higher, But Risks Remain

The TEVA stock price has rebounded on a potential opioid settlement. But consider the company's other risks before buying Teva.

Advanced Micro Devices Stock Is Overvalued, But Could Climb Higher

The upside for Advanced Micro Devices stock is already priced into shares. But continued investor enthusiasm could send AMD stock higher.

‘Cannabis 2.0’ May Not Be Enough to Save Canopy Growth Stock

"Cannabis 2.0" could be the catalyst to save CGC stock. But other factors remain at play. Tread carefully before buying Canopy Growth stock.

PLUG Stock Keeps Getting Hotter, but Shareholders Should Tread Lightly

Plug Power could meet its audacious growth goals. But with high dilution, upside in PLUG stock may be limited. Keep this in mind before entering a position.

With Altria in the Driver’s Seat, It’s Tough to Play Cronos Stock

This makes it tough for average investors to win with Cronos stock. On the other hand, high-short interest may mean its too late to go short CRON. The company's shares could rally in a short squeeze scenario. So what's your play with Cronos stock? Avoid!